• G007-LK: Potent Tankyrase 1/2 Inhibitor for Wnt/β-catenin Re

  2026-05-30

  G007-LK is a highly selective tankyrase 1/2 inhibitor enabling precise modulation of the Wnt/β-catenin signaling pathway and β-catenin degradation in APC-mutant cancer models. Benchmarked in both cell-based and in vivo studies, G007-LK demonstrates nanomolar efficacy and robust antitumor activity.

• Zosuquidar (LY335979) 3HCl: Molecular Precision in P-gp-Medi

  2026-05-29

  Discover how Zosuquidar (LY335979) 3HCl drives molecularly precise inhibition of P-glycoprotein, redefining strategies for overcoming multidrug resistance in cancer. This article offers advanced mechanistic insights and practical assay guidance beyond the standard workflow focus.

• Tyrothricin Peptide Antibiotic: Workflow Mastery & Antimicro

  2026-05-29

  Tyrothricin, a potent peptide antibiotic mixture from APExBIO, bridges fundamental membrane disruption mechanisms with reliable, cross-kingdom infection control. This article empowers researchers with protocol refinements, troubleshooting expertise, and actionable insights drawn from the latest studies and expert workflows.

• CPI-613: Unlocking Cuproptosis and Epigenetic Vulnerabilitie

  2026-05-28

  Discover how CPI-613, a novel mitochondrial metabolism inhibitor, enables advanced apoptosis assays and tumor cell metabolism studies by targeting cuproptosis and epigenetic reprogramming. This article uniquely explores CPI-613’s implications for overcoming drug resistance in cancer research.

• Light-Inducible RNA-Releasing Proteins for Precise Gene Ther

  2026-05-28

  The reference study introduces a rationally engineered light-inducible RNA-releasing protein (LIRP) that enables optogenetic, translation-level regulation of therapeutic gene expression in vivo. This approach provides researchers with temporal, spatial, and reversible control over gene therapies for chronic metabolic and retinal diseases, marking a significant advance in the safety and precision of translational regulation.

• Dual-Action Kinase Inhibitors Promote p38α MAPK Dephosphoryl

  2026-05-27

  This study demonstrates that certain kinase inhibitors, by stabilizing specific inactive conformations of p38α MAP kinase, can enhance its dephosphorylation by phosphatases while simultaneously blocking kinase activity. These findings reveal a new mechanistic link between kinase inhibitor binding, activation loop conformation, and phosphatase accessibility, with significant implications for designing next-generation kinase inhibitors with improved specificity.

• Bestatin Hydrochloride in Tumor and Angiogenesis Research

  2026-05-27

  Bestatin hydrochloride (Ubenimex) is revolutionizing cancer and neurovascular research through its precise inhibition of aminopeptidase N and B. This article delivers actionable protocols, troubleshooting tips, and unique insights from pivotal studies to help you leverage Bestatin hydrochloride for reproducible and high-impact discoveries.

• GSK343 EZH2 Inhibitor: Advanced Workflows for Epigenetic Stu

  2026-05-26

  GSK343, a potent and selective EZH2 inhibitor from APExBIO, empowers cancer and stem cell researchers to interrogate PRC2-mediated gene repression with unmatched precision. This article delivers actionable workflows, troubleshooting strategies, and a translational bridge to recent discoveries in telomerase regulation.

• CRISPR Screens Reveal GRA12 as Key Toxoplasma Virulence Fact

  2026-05-26

  This study systematically identifies GRA12 as a secreted effector essential for Toxoplasma gondii virulence across diverse parasite strains and mouse subspecies. By leveraging in vivo CRISPR-Cas9 screens, the authors uncover mechanisms of immune evasion with broad implications for host-pathogen interaction research.

• Topotecan as a Topoisomerase I Inhibitor: Pharmacology and C

  2026-05-25

  This review details the pharmacological properties and clinical development of topotecan, a water-soluble camptothecin analogue targeting topoisomerase I. The findings clarify topotecan’s mechanism of action, clinical efficacy in solid tumors, and how its unique profile positions it alongside agents like cisplatin in oncology research.

• IPA-3: Transforming Pak1 Pathway Research for Translational

  2026-05-25

  This article explores the selective Pak1 inhibitor IPA-3, its mechanistic specificity, and strategic guidance for translational researchers. Drawing on recent virology and neuroscience evidence, it situates IPA-3 as a crucial tool in dissecting kinase pathways, highlights best practice protocol parameters, and provides a visionary outlook on its role in disease modeling and therapeutic innovation.

• FH1 Small Molecule: Transforming iPSC-Derived Hepatocyte Mat

  2026-05-24

  This article delivers a strategic and mechanistic perspective on how the FH1 small molecule (Catalog No. B3700) from APExBIO is catalyzing a new era in the maturation of iPS cell-derived hepatocytes. By anchoring the narrative in both fundamental biology and translational imperatives, it synthesizes current evidence, protocol optimization, and competitive context—while envisioning future directions that integrate optogenetic control and advanced gene therapy.

• Danazol (Danocrine): Mechanistic and Benchmark Insights for

  2026-05-23

  Danazol (Danocrine), a synthetic steroid with weak androgenic activity, is a proven inhibitor of steroidogenesis and a tool for hypothalamic–pituitary–gonadal axis modeling. Its mechanistic effects on androgen and estrogen pathways are well documented, facilitating its use in endocrine and prostate cancer research.

• PAD4-IN-2 TFA: Advancing Tumor-Targeted NET Inhibition Workf

  2026-05-22

  PAD4-IN-2 TFA enables precision inhibition of histone H3 citrullination and neutrophil extracellular trap (NET) formation, uniquely targeting tumor cells with minimal toxicity. Discover how this meta-phenylboronic acid-modified PAD4 inhibitor streamlines experimental design, empowers tumor immune microenvironment studies, and outperforms earlier PAD4 inhibitors in both selectivity and safety.

• Firefly Luciferase mRNA: Optimizing 5-moUTP Modified Reporte

  2026-05-22

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) sets a new benchmark for robust, low-immunogenicity bioluminescent reporter applications. Leverage advanced design for improved mRNA delivery, translation efficiency, and reproducibility—now with actionable troubleshooting and workflow insights.

16357 records 1/1091 page Next 12345 下5页 Last page